Monopar Therapeutics (MNPR) Liabilities and Shareholders Equity (2016 - 2020)
Historic Liabilities and Shareholders Equity for Monopar Therapeutics (MNPR) over the last 5 years, with Q3 2020 value amounting to $18.2 million.
- Monopar Therapeutics' Liabilities and Shareholders Equity rose 25540.08% to $18.2 million in Q3 2020 from the same period last year, while for Sep 2020 it was $57.1 million, marking a year-over-year increase of 13445.58%. This contributed to the annual value of $13.4 million for FY2019, which is 8245.56% up from last year.
- According to the latest figures from Q3 2020, Monopar Therapeutics' Liabilities and Shareholders Equity is $18.2 million, which was up 25540.08% from $12.8 million recorded in Q2 2020.
- Monopar Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $18.2 million for Q3 2020, and its period low was $2.9 million during Q4 2016.
- Its 5-year average for Liabilities and Shareholders Equity is $9.2 million, with a median of $8.4 million in 2018.
- Per our database at Business Quant, Monopar Therapeutics' Liabilities and Shareholders Equity crashed by 3523.37% in 2019 and then skyrocketed by 25540.08% in 2020.
- Monopar Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $2.9 million in 2016, then soared by 242.98% to $9.9 million in 2017, then dropped by 26.31% to $7.3 million in 2018, then surged by 82.46% to $13.4 million in 2019, then skyrocketed by 35.98% to $18.2 million in 2020.
- Its Liabilities and Shareholders Equity stands at $18.2 million for Q3 2020, versus $12.8 million for Q2 2020 and $12.8 million for Q1 2020.